Drug intelligence / Profile preview

SCD-Omegatex

Development stage: Unknown
Lead developer: Solutex GC
Modality: Small Molecules
Administration: Oral

Overview

SCD-Omegatex is a specialized formulation of omega-3 fatty acids, specifically containing docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), developed for use in children and young adults with sickle cell disease (SCD). The product is manufactured using the active ingredient Solutex0656SCD. Its primary mechanism involves anti-inflammatory and antioxidant effects attributed to DHA and EPA. Clinical studies have shown that supplementation with SCD-Omegatex can reduce vaso-occlusive crises, severe anemia, blood transfusions, white blood cell counts, missed school days, and markers of oxidative stress in patients with sickle cell disease. The formulation aims to improve quality of life by reducing pain sensitivity and providing antioxidant protection[1][2].

Brand names: SCD-Omegatex

Beyond the preview

Go deeper on SCD-Omegatex.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SCD-Omegatex.

Explore the full profile